trending Market Intelligence /marketintelligence/en/news-insights/trending/_mx2XIqjf5MfJlWP6_nAWg2 content esgSubNav
In This List

Aerie Pharmaceuticals raises $125M

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Aerie Pharmaceuticals raises $125M

Aerie Pharmaceuticals Inc. priced and upsized a previously announced offering by $25 million to $75 million.

Each share issued under the offering will be sold at $53.75 apiece, with the issue to be closed by June 1.

Aerie Pharmaceuticals sold a further $50 million via an at-the-market program via Cantor Fitzgerald & Co. that is expected to close by May 31.

Aerie plans to use the net proceeds from the offerings for general corporate purposes, including the commercialization and clinical efforts for its products Rhopressa and Roclatan.

Cantor Fitzgerald & Co. is the sole book runner for both transactions.